| Excerpt | Reference |
|---|
| "A case of acquired hemophilia is presented." | ( Frohnsdorff, KG; Seth, HK, 1977) |
| "Haemophilia is a rare and complex disorder and its successful management will depend upon the establishment of a network of 'comprehensive care' including the services of haematologists, orthopaedic surgeons, rheumatologists, dental surgeons, physiotherapists, specialised nurses and counsellors." | ( Winter, M, 1992) |
| "Acquired factor VIII deficiency is a rare immunologic disorder characterized by severe bleeding due to an antibody inhibitor directed against factor VIII." | ( Lalwani, RB; Stricker, RB, 1992) |
| "Hemophilia is an inherited coagulation disease that affects approximately 1 in 5,000 to 10,000 males worldwide." | ( Alperin, JB; Buchanan, GR; Hoots, WK; Kletzel, M; Parmley, RT; Sexauer, CL, 1991) |
| "Hemophilia is a hereditary coagulopathy which has the characteristic of bleeding into various tissues, particularly joints and muscles, bearing the risk of early invalidity." | ( Gebauer, E; Katanić, D, 1990) |
| "Haemophilia is a congenital, life-long disorder that may cause major disabilities." | ( Dietrich, SL; Kasper, CK, 1985) |
| "Haemophilia is characterized by recurrent internal bleeding episodes, with repeated haemorrhages into the joint areas eventually resulting in a chronic condition similar to osteoarthritis." | ( Gilbert, A; Varni, JW, 1982) |
| "Hemophilia is a life-long bleeding disorder carried by females and passed on to their male offspring which consists of spontaneous internal hemorrhages." | ( Goldman, E; Lee, CA; Miller, R, 1993) |
| "Many patients with haemophilia are infected with viruses, due to treatment with blood products--particularly from large pool clotting factor concentrates before 1985." | ( Lee, CA, 1996) |
| "Acquired hemophilia is a rare disorder associated with serious bleeding in nonhemophilic patients." | ( Cho, SH; Chung, IJ; Kim, HJ; Lee, JJ; Park, MR; Ryang, DW; Yang, DH, 2000) |
| "Acquired haemophilia is a rare, life-threatening, acquired bleeding diathesis." | ( Beneke, H; Brommer, A; Germowitz, A; Griesshammer, M; Grünewald, M; Güthner, C, 2001) |
| "The hemophilias are characterized by specific sex-linked patterns of inheritance, and there are sex differences in the presentation of the autosomally inherited disorders, particularly von Willebrand's disease." | ( Seremetis, SV, 2001) |
| "Haemophilia is characterized by intra-articular bleeding, often requiring immobilization, which may result in muscle atrophy and impaired proprioception." | ( Gabriel, HH; Herbsleb, M; Hilberg, T; Jeschke, D; Schramm, W, 2001) |
| "Hemophilia is a rare disorder affecting 1 in 5,000 males." | ( Hammond, L; Hoffman, R; Nuss, R, 2002) |
| "Hemophilia is an inherited bleeding disorder caused by quantitative or qualitative defects in the synthesis of factor VIII (FVIII) or factor IX (FIX)." | ( Petrini, P, 2002) |
| "Hemophilia is a rare congenital bleeding disorder that is due to the deficiency of blood coagulation factor VIII or IX." | ( Chen, YX; Jabbar, AA; Kazarian, T; Patel, DA; Valentino, LA; Wen, FQ, 2002) |
| "Haemophilia is the most serious bleeding model that nature has provided us with, indicating the importance of factor FVIII and FIX in haemostasis." | ( Hedner, U, 2002) |
| "Severe haemophilia is a serious, haemorrhagic disorder of the plasmatic coagulation system." | ( Griesshammer, M; Grünewald, A; Grünewald, M; Koksch, M; Konegen, A; Siegemund, A, 2002) |
| "When mild haemophilia is suspected, discrimination may be improved by diluting both the patient's and the control plasmas 1 in 20 in haemophilic plasma." | ( INGRAM, GI; MATCHETT, MO, 1965) |
| "Acquired haemophilia is a rare bleeding diathesis caused by auto-immune depletion of factor VIII." | ( Bellon, B; Bonnet, E; Cestac, P; DeRoch, XS; Favre, V; Khatibi, S; Laporte, F; Massip, P; Sie, P, 2003) |
| "Acquired hemophilia is a rare, life threatening coagulopathy in adults caused by the development of autoantibodies against to factor VIII." | ( Ali, R; Ozan, U; Ozçelik, T; Ozkalemkas, F; Ozkocaman, V; Saricaoğlu, H; Tunali, A; Yalçin, M, 2003) |
| "Hemophilia is a genetic disease caused by a deficiency of blood coagulation factor VIII or IX." | ( Hakobyan, N; Jabbar, AA; Jabbar, KJ; Kazarian, T; Valentino, LA, 2004) |
| "Comprehensive haemophilia care has been defined as the continuing supervision of all medical and psychosocial factors affecting the person with haemophilia family." | ( Batorova, A; Black, C; Evatt, BL; Srivastava, A; Street, A, 2004) |
| "Likewise, acquired factor VIII deficiency is a rare antibody-mediated disease of adulthood." | ( Cohen, JB; Maize, JC, 2005) |
| "Acquired haemophilia is a rare phenomenon and prompt diagnosis is essential for successful treatment." | ( Brooks, S; Brown, S; Lee, C; Riddell, A; Vadikolia, CM; Yee, TT, 2007) |
| "Acquired hemophilia is a rare entity in childhood." | ( Asal, GT; Ersoy, F; Gurgey, A; Ozgur, TT; Sanal, O; Tezcan, I, 2007) |
| "Hemophilia is a serious bleeding disorder and patients with hemophilia develop repeated spontaneous CNS, joint and muscle bleeding." | ( Brun, NC; Hedner, U, 2007) |
| "As comprehensive haemophilia care is multidisciplinary by nature, the need for education and research programmes for all staff members is emphasized: Members of the Interdisciplinary Working Group not represented in the list of authors are mentioned in Section 4 of this document." | ( Astermark, J; Colvin, BT; Fischer, K; Gringeri, A; Ingerslev, J; Lassila, R; Schramm, W; Thomas, A, 2008) |
| "Hemophilia is traditionally classified according to the levels of the deficient coagulation factor as Severe (<1%), Moderate (1-5%) or Mild (>5%)." | ( Chitlur, M; Hollon, W; Llanto, L; Lusher, JM; Rajpurkar, M; Warrier, I; Wiseman, C, 2008) |
| "Acquired haemophilia is an autoimmune disorder characterised by autoantibody formation against coagulation factor VIII." | ( Alberio, L; Brand, B; Geisen, U; Grossmann, R; Huth-Kühne, A; Klamroth, R; Knöbl, P; Krause, M; Oldenburg, J; Spannagl, M; Tiede, A, 2009) |
| "Individuals with haemophilia are frequently infected with both human immunodeficiency virus (HIV) and hepatitis C virus (HCV); however, limited evidence is currently available regarding the efficacy of HCV treatment with pegylated interferon and ribavirin in this patient population." | ( Denholm, JT; Sasadeusz, JJ; Street, A; Wright, EJ, 2009) |
| "The hallmark of haemophilia is the joint morbidity resulting from haemarthrosis that accounts for the majority of the bleeds." | ( Jensen, AL; Kristensen, AT; Tranholm, M; Øvlisen, K, 2009) |
| "Mild haemophilia is defined by factor levels between 0." | ( Jacquemin, M; Peerlinck, K, 2010) |
| "Acquired hemophilia is associated with various underlying conditions, but our patient did not show any previous history." | ( Miura, I; Nagoshi, H; Nagura, S; Sano, F; Takimoto, M, 2010) |
| "Hemophilia is a hereditary disease in which circulating levels of coagulation factors are lacking, resulting in a propensity toward bleeding." | ( Adams, JE; Reding, MT, 2011) |
| "Hemophilia is an X-linked bleeding disorder caused by a deficiency of factor VIII or IX activity." | ( Card, R; Poon, MC, 2012) |
| "Hemophilia is treated by IV replacement therapy with Factor VIII (FVIII) or Factor IX (FIX), either on demand to resolve bleeding, or as prophylaxis." | ( Balling, KW; Bjørn, SE; Bowler, AN; Breinholt, J; Clausen, JT; Egebjerg, T; Ezban, M; Friederichsen, B; Gruhler, A; Hansen, L; Hermit, MB; Hilden, I; Jespersgaard, C; Krogh, BO; Lauritzen, B; Petersen, HH; Petersen, LC; Svensson, LA; Sørensen, BB, 2012) |
| "Acquired hemophilia is a severe bleeding diathesis caused by autoantibodies against a coagulation factor VIII (FVIII inhibitor)." | ( Drobiecki, A; Hus, I; Pasiarski, M; Sokołowska, B; Wątek, M, 2013) |
| "Acquired factor VIII deficiency is a rare disease that has high rates of mortality and morbidity." | ( Nable, JV; Pham, TV; Sorenson, CA, 2014) |
| "Haemophilia is characterised by defective thrombin generation, reduced clot stability and spontaneous bleeding." | ( Bevan, DH; Foley, JH; Rea, CJ; Sørensen, B, 2014) |
| "Patients with haemophilia are at least as vulnerable as other chronic pain populations to opioid-related adverse events and to developing abusive behaviours and addiction." | ( Humphries, TJ; Kessler, CM, 2015) |
| "Acquired haemophilia is a rare but life-threatening phenomenon in patients who have undergone surgical treatment." | ( Beishuizen, A; Klaase, JM; Legdeur, MC; Mekenkamp, LJ; Slomp, J; Trof, RJ, 2015) |
| "Hemophilia is the most common inherited coagulation disorder, and approximately one-half of patients are diagnosed as newborns." | ( Jesic, MM; Jovandaric, MZ, 2015) |
| "Haemophilia is caused by deficiency in coagulation factor VIII or IX." | ( Baghaei, F; Brodin, E; Sunnerhagen, KS; Törnbom, M, 2015) |
| "Acquired haemophilia is a rare coagulation disorder more commonly seen in elderly patients." | ( Benson, G; Lawless, S, 2015) |
| "Hemophilia is a genetic disorder with high health care burden." | ( Mukherjee, K; Singh, P, 2017) |
| "Acquired hemophilia is a rare but potentially life-threatening bleeding disorder caused by the development of autoantibodies (inhibitors) directed against plasma coagulation factors, most frequently factor VIII." | ( Claroni, C; Covotta, M; Forastiere, E; Naccarato, A; Pelagalli, L; Torregiani, G; Tribuzi, S, 2017) |
| "BACKGROUND Acquired hemophilia is a rare but potentially dangerous bleeding disorder caused by autoantibodies against coagulation factors." | ( Botross, NP; Hoong, CK; Lim, SM; Loong, JLX; Stephen, SE, 2018) |
| "Hemophilia is an inherited genetic disease characterized by the inability to coagulate blood after injury." | ( Al-Ghamdi, MA; Huwait, EA; Kumosani, AT; Kumosani, TA; Moselhy, SS; Qari, M, 2018) |
| "Haemophilia is a common hereditary cause of bleeding diathesis and the musculoskeletal system is frequently affected." | ( Colville, JG; Hartley, R; Ray, A; Rowbotham, E, 2022) |
| "Hemophilia is a rare hereditary bleeding disorder that develops as a result of factor VIII or IX deficiency." | ( Buget, MI; Canbolat, N; Dinç, T; Kılıçoğlu, Öİ; Koç, B; Koltka, K; Zulfikar, B, 2022) |
| "Hemophilia is a rare inherited disease which causes bleeding due to Factor VIII or Factor IX deficiency." | ( Cüre, O; Ilkkilic, K, 2023) |
| "Hemophilia is the best known of the inherited bleeding disorders (BD)." | ( Benson, CC; Boice, JA; Chitlur, M; Dunn, AL; Escobar, MA; Gupta, K; Johnsen, JM; Jorgenson, J; Martin, S; Martin, SD; Meeks, SL; Narvaez, AA; Quon, DV; Reding, MT; Reiss, UM; Savage, B; Schafer, K; Steiner, B; Thornburg, C; Tran, DQ; Volland, LM; von Drygalski, A, 2023) |
| "Hemophilia is an inherited bleeding disorder caused by deficiency of a specific coagulation factor." | ( Angchaisuksiri, P; Moonla, C; Natesirinilkul, R; Pongtanakul, B; Sirachainan, N; Sosothikul, D; Suwanawiboon, B; Traivaree, C, 2023) |
| "Hemophilia is an X-linked recessive inherited disease affecting the coagulation pathway due to congenital deficiencies in either factor VIII (hemophilia A) or factor IX (hemophilia B)." | ( Laha, G; Mehta, G; Pancholi, V; Rathod, VM; Raval, DM; Shastri, M; Vasava, R, 2023) |
| Excerpt | Reference |
|---|
| "Three children with haemophilia and antibodies to factor VIII were treated with a non-activated prothrombin concentrate (Prothrombinex) for 12 bleeding episodes." | ( d'Souza, S; Ekert, H; Price, DA, 1977) |
| "A female carrier of haemophilia A with known bleeding diathesis and markedly reduced factor VIII activity was successfully treated with DDAVP during bilateral Caldwell-Luc's operation for chronic maxillary sinusitis." | ( Sauer, E; Theiss, W, 1977) |
| "This report describes two patients with haemophilia A who developed a transient thrombocytopathy with haemorrhagic diathesis during post-operative high-dose replacement therapy with antihaemophilic globulin." | ( Gadner, H; Jarofke, R; Odenwald, E; Riehm, H, 1977) |
| "Bleeding episodes in patients with hemophilia A with anti-factor VII antibodies are frequently difficult to treat." | ( Blatt, PM; McMillan, CW; Roberts, HR; White, GC, 1977) |
| "Nine patients with severe classic hemophilia and inhibitors against factor VIII were treated for 156 bleeding episodes with 503 infusions of Proplex, Konyne, or Auto-Factor IX, three preparations of prothrombin complex concentrates (PCCs)." | ( Buchanan, GR; Kevy, SV, 1978) |
| "Three severely affected haemophiliacs who had developed antibodies to factor VIII are described in whom the administration of cyclophosphamide was thought to have prevented reappearance of the antibody after factor VIII infusion." | ( Dormandy, KM; Sultan, Y, 1975) |
| "Hemorrhage into the hand and forearm in hemophiliacs can be devastating if not treated early and properly." | ( Gilbert, MS; Lancourt, JE; Posner, MA, 1977) |
| "Two severe hemophiliacs with low titer inhibitors that disappeared without specific therapy are also reported." | ( Andrews, AT; Bowman, HS; Eyster, EM; Gill, FM; Hultin, MB; Martinez, J; Shapiro, SS; Sherwood, WC, 1976) |
| "SETTING--Haemophilia treatment centres in six large American cities." | ( Aledort, LM; Gjerset, GF; Hilgartner, MW; Koerper, MA; Lian, EY; Lusher, JM; Mosley, JW; Pike, MC, 1992) |
| "When patients with mild haemophilia or von Willebrand disease (vWD) are repeatedly treated with desmopressin (DDAVP) at relatively short time intervals, some of them may become less responsive or unresponsive." | ( Bettega, D; Cattaneo, M; Mannucci, PM, 1992) |
| "A 14-year-old male HIV-positive hemophilia A patient, who was complicated by disseminated intravascular coagulation syndrome (DIC) following acute pancreatitis during treatment for PCP, was treated with proteinase inhibitors and anticoagulant agents." | ( Fukue, H; Koshihara, K; Matsumoto, K; Suzuki, T; Takahashi, Y; Tanaka, A; Tateyama, M; Yamagishi, T; Yorifuji, H; Yoshida, S, 1992) |
| "Plasmas from patients with haemophilia B, on coumarin treatment, with liver cirrhosis were studied." | ( Girolami, A; Lazzaro, AR; Ruzza, G; Viero, ML, 1990) |
| "The joint problems in haemophiliacs are solved by the prophylactic treatment in an incomplete manner only." | ( Weissbach, G; Wendisch, J; Zimmer, T, 1990) |
| "Because older patients with hemophilia have more rapid disease progression, the same efficacy analysis was performed in the 89 patients aged more than 30 years who were receiving treatment." | ( Amato, DA; Balsley, J; Benoit, S; Brettler, D; Brownstein, A; Kramer, AS; Merigan, TC; Perez-Michael, A; Power, M; Price, WA, 1991) |
| "Services of every "comprehensive" hemophilia treatment center (HTC) have expanded since previous treatment with clotting factor concentrates infected many hemophilics with the human immunodeficiency virus (HIV)." | ( Alperin, JB; Buchanan, GR; Hoots, WK; Kletzel, M; Parmley, RT; Sexauer, CL, 1991) |
| "Sixteen anti-HIV positive patients (15 haemophiliacs and one blood transfusion recipient) with a clinical diagnosis of oropharyngeal candidiasis were treated with 50 mg fluconazole daily for 14-28 days and then either 150 mg fluconazole or placebo weekly for 6 months in a prophylactic phase." | ( Hales, M; Kernoff, PB; Lee, CA; Lim, SG; O'Doherty, M; Winter, M, 1991) |
| "Regional, comprehensive, hemophilia diagnosis and treatment center." | ( Aledort, LM; Rose, EH, 1991) |
| "In patients with hemophilia, the level of factor VIII activity was measured; in patients with von Willebrand disease, levels of factor VIII activity, ristocetin cofactor activity, and von Willebrand antigen as well as bleeding time were measured before and after each administration of desmopressin." | ( Aledort, LM; Rose, EH, 1991) |
| "This form of treatment is suggested for hemophiliacs who have failed to respond to intensive physical and hematologic therapy, and for those patients who have inhibitors." | ( Erken, EH, 1991) |
| "Twenty haemophiliacs (17 CDC group IV and 3 CDC group II) were treated with zidovudine for a median of 37 weeks (range 10-66)." | ( Kernoff, PB; Lee, CA; Lim, SG, 1990) |
| "20 cases of hemophilia, including ten of hemophilia A , nine of hemophilia B and one of von Willebrand's disease (VWD), were treated with ranitidine." | ( Hu, LM; Xu, B; Ye, LL, 1990) |
| "Forty-two hemophiliacs with HIV infection were treated with high-dose glycyrrhizin, Stronger Neo-Minophagen C (SNMC)." | ( Aihara, M; Akutsu, Y; Imaizumi, M; Ishikawa, M; Mori, K; Sakai, H; Sawada, Y; Suzuki, S; Tada, K; Yokoyama, M, 1990) |
| "In a patient with severe haemophilia B and antibodies against factor IX in high titre, and known for many years to be a really high responder, it was possible to suppress the secondary antibody response after treatment with high doses of intravenous IgG (Gammonativ, KabiVitrum AB) combined with factor IX and cyclophosphamide." | ( Nilsson, IM; Sundqvist, SB; Zettervall, O, 1985) |
| "From 1975 to 1986 we studied 12 nonhemophiliac and 5 hemophiliac patients with factor VIII inhibitor treated with FVIII-CVP and followed at our clinic." | ( Chiu, AY; Larcada, AF; Lian, EC, 1989) |
| "Patients with hemophilia A or von Willebrand's disease who are treated with concentrated preparations of human factor VIII made from unscreened pooled plasma are at substantial risk of contracting human immunodeficiency virus (HIV) infection." | ( Auerswald, G; Brackmann, HH; Haschke, F; Koehler, K; Kraus, B; Kreuz, W; Moesseler, J; Schimpf, K; Schramm, W; Sutor, AH, 1989) |
| "In consequence hemophilia treatment has been improving rapidly since, and today most life-threatening hemorrhages are controlled by replacement therapy." | ( Meili, EO, 1989) |
| "Thirty six hemophiliacs with HIV infection were treated with high-dose glycyrrhizin, Stronger Neo-Minophagen C (SNMC)." | ( Aihara, M; Akutsu, Y; Endo, Y; Ishikawa, M; Mori, K; Okaniwa, S; Sakai, H; Sato, Y; Suzuki, S; Yokoyama, M, 1989) |
| "On the other hand, in 3 cases of hemophilia without HIV infection, the number of OKT4 lymphocytes was not significantly altered during treatment." | ( Akutsu, Y; Ishida, N; Ishikawa, M; Kariyone, S; Mori, K; Sakai, H; Seino, Y; Sugai, K; Suzuki, S; Uchida, T, 1989) |
| "During this time, none of 8 untreated hemophiliacs and none of 26 hemophiliacs treated solely with cryoprecipitates had antibody to LAV." | ( Evatt, BL; Lederman, MM; McDougal, JS; Ratnoff, OD, 1985) |
| "The bleeding disorder of hemophilia A currently treated by replacement therapy of the missing coagulation factor, factor VIII, is frequently complicated by the development of neutralizing antibodies." | ( Giles, AR; O'Brien, DP; Tate, KM; Vehar, GA, 1988) |
| "Forty-two male homosexuals and/or hemophiliacs with depressed helper/suppressor T-cell ratios were treated with one of three different doses of thymosin fraction 5 (TF5, 30, 60, and 120 mg), or a single dose of thymosin Alpha One (TA1, 600 micrograms), by daily subcutaneous (SQ) administration for 10 weeks, followed twice weekly for 4 weeks." | ( Courtless, JW; DiGioia, RA; Kessler, CM; Kind, PD; Orenstein, JM; Parenti, DM; Schlesselman, S; Schulof, RS; Simon, GL; Sztein, MB, 1986) |
| "An 18-year-old man with mild factor VIII deficiency developed hematuria and, subsequently, acute renal failure due to high-grade urinary obstruction by clots during therapy with cryoprecipitate, epsilon-aminocaproic acid, and acetazolamide administered for ocular trauma." | ( Bontempo, FA; Greenberg, A; Pitts, TO; Spero, JA, 1986) |
| "Amongst 160 English haemophiliacs treated with clotting factor concentrates, abnormalities of T lymphocyte subset distribution (characterized by low T4/T8 ratios and high total T8 counts), low in vitro phytohaemagglutinin stimulation and raised serum IgG levels, were more common in patients with haemophilia A than B, in patients who had received heavier blood product exposure, and in adults rather than children." | ( Bofill, M; Janossy, G; Kernoff, PB; Lee, CA; Rizza, CR; Thomas, HC, 1985) |
| "The treatment of haemophilia has been dramatically improved since the introduction of factor VIII and IX concentrates, however these concentrates have brought new problems such as hepatitis and A." | ( Forbes, CD; Greaves, M; Greer, IA; Lowe, GD; Madhok, R; McLoughlin, K; Porter, N; Preston, FE, 1985) |
| "Under intensive substitution therapy of haemophilia A the so-called paradoxical bleeding will occur in spite of a high factor VIII level." | ( Domula, M; Lenk, H; Weissbach, G, 1981) |
| "Two patients with hemophilia A complicated with high-titer alloantibodies have been treated by repeated infusions of microgram quantities of pure human Factor VIIa." | ( Hedner, U; Kisiel, W, 1983) |
| "In 7 haemophiliacs with pretreatment levels of FVIII: C ranging from between 11 and 43% dental extractions were performed successfully after DDAVP whereas in 2 patients with FVIII: C levels of 5 and 6%, respectively, severe bleeding necessitated administration of factor VIII concentrates." | ( Korninger, C; Niessner, H, 1983) |
| "Treatment of hemophilia and von Willebrand's disease has become easier in recent years because of the development of more effective factor replacement products." | ( Gill, FM, 1984) |
| "Repeatedly-treated haemophiliacs and VWD patients showed varied patterns, ranging from no change of the response to its early abolishment." | ( Canciani, MT; Donovan, BS; Mannucci, PM; Rota, L, 1981) |
| "Three patients with severe hemophilia A with inhibitors to factor VIII were treated with activated factor IX complex." | ( Hanna, WT; Lange, RD; Madigan, RR; Miles, MA, 1981) |
| "Thirty-three hemophilia treatment centers throughout the United States." | ( Agle, DP; Drotar, DD; Eckl, CL; Thompson, PA, 1995) |
| "Evidence suggests that haemophiliacs treated with factor VIII concentrates show abnormalities in immune functions." | ( Barrowcliffe, TW; Mire-Sluis, AR; Thorpe, R; Wadhwa, M, 1995) |
| "Blood from patients with acquired factor VIII deficiency and Glanzmann's thrombasthenia and from those receiving Coumadin therapy were also studied." | ( Gabriel, DA; Melton, LG; Muga, KM, 1995) |
| "Blood samples were obtained from 16 hemophiliacs who had a 50%-94% defined risk of human immunodeficiency virus (HIV) type 1 infection on the basis of treatment history and from 14 controls not at risk for HIV infection." | ( Aledort, LM; Cohen, AR; Eyster, ME; Hilgartner, MW; Jackson, JB; Kessler, CM; Kiger, KP; Kroner, BL; Lederman, MM; White, GC, 1995) |
| "To abolish inhibitors, 40 out of 60 hemophiliacs (57 patients and 3 with hemophilia A and B, respectively) were treated according to the therapeutic scheme specified as Bonn protocol." | ( Brakman, GG, 1993) |
| "In July 1992, the National Hemophilia Foundation and CDC received a report from a hemophilia-treatment center of a 19-year-old man with hemophilia (patient 2) who recently had seroconverted for antibody to human immunodeficiency virus (HIV)." | ( , 1993) |
| "In the treatment of a hemophilia B patient showing decreased platelet counts, these counts increased consistent with the administration of Acyclovir and Zidovudine." | ( Fukutake, K; Koike, K; Sugimura, D; Takahashi, Y; Tateyama, M; Yamamoto, Y; Yorifuji, H; Yoshida, S, 1993) |
| "Sixty-five patients with haemophilia A from Singapore General Hospital, treated within the last 15 years exclusively with cryoprecipitate, were studied for the effect of the total number of exposures to random blood donors on their immune system." | ( Ong, YW; Tan, H; Tan, P; Tien, SL, 1993) |
| "Five hemophilia treatment centers in the United States." | ( Aledort, LM; Blattner, WA; Cohen, AR; Eyster, E; Goedert, JJ; Hatzakis, A; Hilgartner, MW; Kroner, BL; Luban, N; Miley, WJ; O'Brien, TR; Rosenberg, PS; Waters, D, 1996) |
| "Many patients with haemophilia are infected with viruses, due to treatment with blood products--particularly from large pool clotting factor concentrates before 1985." | ( Lee, CA, 1996) |
| "Seven of 112 hemophiliacs infected with human immunodeficiency virus type-1 (HIV-1) before 1986 through contaminated plasma products are currently healthy, with CD4 T-cell counts above 500 cells/microL, and have never received antiretroviral therapy (long-term nonprogressors [LTNPs])." | ( Alfano, M; Bagnarelli, P; Clementi, M; Fabio, G; Ghezzi, S; Gringeri, A; Lazzarin, A; Mannucci, PM; Mantovani, A; Moretti, G; Poli, G; Santagostino, E; Sinnone, MS; Turchetto, L; Vicenzi, E, 1997) |
| "We have developed artificial hemophilia in zebrafish by treating them with copper and measured their clotting function by a newly developed sensitive clotting time assay." | ( Jagadeeswaran, P; Liu, YC, 1997) |
| "A 42-year-old patient with mild hemophilia A developed spontaneous muscle hematomas 1 month after intense therapy with factor VIII concentrates." | ( Healey, JF; Liu, M; Lollar, P; Murphy, ME; Saenko, EL; Scandella, D; Thompson, AR, 1997) |
| "A 16-year-old white hemophiliac boy with HIV infection secondary to tainted coagulation factor VIII was treated with indinavir sulfate." | ( Ascher, DP; Lucy, MD, 1997) |
| "Eight Japanese hemophiliacs with chronic hepatitis C (CHC) received interferon (IFN) therapy and four of them (50%) responded completely." | ( Meguro, T; Miura, T; Takayama, S; Yamada, K, 1997) |
| "Current therapies for treatment of hemophilia A involve infusion of factor VIII, but are ineffective for patients who develop inhibitory antibodies." | ( Laibelman, AM; Lin, PH; Sinha, U, 1997) |
| "A 29-year-old hemophiliac with HIV infection for which he was receiving antiretroviral treatment (ART) with indinavir, zidovudine and zalcitabine reported increasing swelling of the neck." | ( Fischer, T; Ramadori, G; Schwörer, H, 1998) |
| "The ultimate goal in the treatment of haemophilia patients with inhibitors is to eradicate permanently the inhibitor and induce tolerance." | ( Berntorp, E; Ekman, M; Freiburghaus, C; Gunnarsson, M; Kjellberg, B; Nilsson, IM, 1999) |
| "We describe a patient with acquired haemophilia who developed acute renal failure rapidly after treatment with a high sucrose content IVIG preparation." | ( Bainton, R; Laidlaw, S; Makris, M; Wilkie, M, 1999) |
| "Twelve HIV+ hemophilia patients before and after conversion to HAART (group 1); eight HIV+ hemophilia patients without antiretroviral therapy (group 2)." | ( Daniel, V; Huth-Kühne, A; Kröpelin, M; Melk, A; Opelz, G; Süsal, C; Uhle, C; Weimer, R; Zimmermann, R, 1999) |
| "DDAVP may be contraindicated in mild Haemophilia and von Willebrand patients for treatment of traumatic hyphaema." | ( Bolton-Maggs, PH; Hallet, C; Kaye, SB; Shafiq, A; Willoughby, C, 2000) |
| "Many persons with haemophilia suffer from HIV and receive highly active antiretroviral therapy." | ( Heim, M; Martinowitz, U; Schapiro, J; Wershavski, M, 2000) |
| "Inhibitor formation in patients with haemophilia receiving factor VIII (FVIII) concentrate is a common problem requiring tolerance induction therapy." | ( Han, P; Hodge, G, 2000) |
| "Hepatitis C virus (HCV) infected hemophiliacs respond at low rate to interferon (IFN) monotherapy." | ( Altisent, C; Esteban, JI; Esteban, R; Guardia, J; Puig, L; Sauleda, S, 2000) |
| "Patients with severe haemophilia, who visit the Van Creveldkliniek on a regular basis, were administered the D-AIMS2." | ( de Joode, EW; de Kleijn, P; Helders, PJ; van den Berg, HM; van Meeteren, NL, 2001) |
| "The clinical experience of three haemophilia centres which used rifampicin for the treatment of chronic haemophilic synovitis is presented here." | ( Caviglia, HA; Fernandez-Palazzi, F; Galatro, G; Perez-Bianco, R, 2001) |
| "The long-term outcome of patients with hemophilia who were treated with phosphate-32 chromic phosphate radiosynovectomy was evaluated." | ( Luck, JV; Quinones, C; Siegel, HJ; Siegel, ME, 2001) |
| "Thirty-nine hemophiliac patients, negative for human immunodeficiency virus, with chronic hepatitis C who failed to respond to interferon (IFN) at 3 million units (MU) given subcutaneously thrice weekly for at least 3 months were retreated with 5 MU IFN for 6 months followed by 3 MU IFN in combination with daily oral doses of 1 or 1." | ( Colombo, M; Mannucci, PM; Rivi, M; Rumi, MG; Santagostino, E, 2002) |
| "The main goal of hemophilia treatment is to prevent bleeding symptoms and allow normal integration in social life." | ( Petrini, P, 2002) |
| "The fourth, a patient with mild hemophilia A, developed both an autoantibody and an alloantibody following recombinant FVIII treatment." | ( Asch, AS; Cho, HJ; Michelis, MA; Peerschke, EI; Schechter, GP; Weksler, BB; Wiestner, A; Zeller, JA, 2002) |
| "Not all hemophilia A patients can be treated." | ( Lethagen, S, 2003) |
| "In 1996, 12 HIV(+) hemophilia patients were converted to highly active antiretroviral therapy (HAART), while 10 other patients were maintained on conventional antiretroviral treatment and another 11 patients refused to be treated with antiretroviral drugs." | ( Daniel, V; Huth-Kühne, A; Naujokat, C; Opelz, G; Sadeghi, M; Süsal, C; Weimer, R; Zimmermann, R, 2004) |
| "We wish to report a single paediatric haemophilia treatment center's results of treatment of adolescents with haemophilia and hepatitis C infection with combination therapy." | ( Bouhasin, J; Kane, R; Puetz, J; Thrower, M, 2004) |
| "Thirty-four previously untreated, adult hemophiliacs with chronic HCV but negative for HIV were investigated." | ( Colombo, M; De Filippi, F; Mannucci, PM; Rivi, M; Rumi, MG; Santagostino, E, 2004) |
| "We suggest that acquired hemophilia due to factor VIII inhibitor(s) should be considered in the appropriate setting when patients present with unexplained and even minor bleeding while on treatment with acetaminophen or chlorpheniramine alone or combined." | ( De Maria, S; Famularo, G; Minisola, G; Nicotra, GC, 2004) |
| "We designed a haemophilia A gene therapy strategy involving the genetic modification of haematopoietic stem cells to achieve tissue-specific expression of a factor VIII (FVIII) transgene in the megakaryocytic lineage." | ( Enjolras, N; Leboeuf, M; Négrier, C; Plantier, JL; Réa, M; Rodriguez, MH; Uzan, G, 2004) |
| "Virtually all haemophiliacs who received non-virucidally treated, large-pool clotting factor concentrates before 1986 became infected with hepatitis C virus (HCV)." | ( Franchini, M, 2004) |
| "Before the mid-1980s, haemophilia often was unknowingly treated with contaminated plasma products, resulting in high rates of human immunodeficiency virus (HIV-1), hepatitis C virus (HCV) and hepatitis B virus (HBV) infections." | ( Goedert, JJ, 2005) |
| "Although hemophilia A mice were not predictive of vector efficacy in dogs, the two treated male dogs became symptom-free for long periods." | ( Addya, S; Bellinger, DA; Kazazian, HH; Mucci, M; Nichols, TC; Sarkar, R; Tetreault, R, 2006) |
| "Acquired haemophilia is a rare phenomenon and prompt diagnosis is essential for successful treatment." | ( Brooks, S; Brown, S; Lee, C; Riddell, A; Vadikolia, CM; Yee, TT, 2007) |
| "Twenty-one hemophiliacs on prophylactic factor treatment without recent bleeds were subjected to radiography and gadolinium contrast-enhanced dynamic and static MRI of the knee using a standard dose of 0." | ( Berntorp, E; Jonsson, K; Ljung, R; Lundin, B; Pettersson, H; Ståhlberg, F; Wirestam, R, 2007) |
| "Both the acquired hemophilia A and MCNS responded well to the treatment with prednisolone." | ( Gohda, F; Handa, H; Irisawa, H; Karasawa, M; Matsushima, T; Murakami, H; Nojima, Y; Osaki, Y; Saitoh, T; Shimizu, H; Tsukamoto, N; Uchiumi, H; Yamane, A; Yokohama, A, 2007) |
| "This study involved 12 hemophiliacs who were treated for hemophilic joint disease with 14 RSOs by using (186)Re colloid." | ( Brecelj, J; Fettich, J; Grmek, M; Milcinski, M, 2007) |
| "Hepatitis C virus-infected haemophiliacs are traditionally under represented in international treatment studies thus data assessing response to pegylated-interferon (peg-IFN) and ribavirin (RBV) in HCV mono-infected or HCV/HIV co-infected haemophiliacs are few." | ( Bergin, C; Farrell, G; Hopkins, S; Kevans, D; Mahmud, N; Norris, S; White, B, 2007) |
| "Males (12-60 years) with severe hemophilia A received a single infusion of standard rFVIII-FS (35 IU kg(-1)) followed by a single infusion of BAY 79-4980 (13 or 22 mg kg(-1) pegylated liposomes) or vice versa, with 12 observation days and a 2-day washout period between treatments." | ( Gorina, E; Harrison, JA; Luk, A; Nugent, DJ; Powell, JS; Soni, A; Stass, H, 2008) |
| "Thus, in every patient with haemophilia A likely to be treated or candidate to an elective invasive procedure, a test-infusion/injection should be carried out to assess the future usefulness of the compound." | ( Castaman, G, 2008) |
| "For the treatment of haemophilia patients with inhibitors, recombinant factor VIIa (rFVIIa) is available as a therapeutic option to control bleeding episodes with a good balance of safety and efficacy." | ( Kronthaler, U; Lang, W; Liebing, U; Schulte, S; Weimer, T; Wormsbächer, W, 2008) |
| "The correct diagnosis of factor VIII deficiency and the assessment of severity of the disease are essential for a patient-tailored treatment strategy." | ( Meijer, P; Novákova, I; Van Heerde, W; Verbruggen, B, 2008) |
| "Patients with haemophilia A treated prophylactically require frequent factor VIII (FVIII) infusions for bleed protection." | ( Andreeva, TA; Khametova, RN; Plyushch, OP; Spira, J, 2008) |
| "Individuals with haemophilia are frequently infected with both human immunodeficiency virus (HIV) and hepatitis C virus (HCV); however, limited evidence is currently available regarding the efficacy of HCV treatment with pegylated interferon and ribavirin in this patient population." | ( Denholm, JT; Sasadeusz, JJ; Street, A; Wright, EJ, 2009) |
| "In this review, haemophilia-related and non-haemophilia-related medical problems, treatment recommendations and psychosocial consequences in ageing haemophilia patients are discussed." | ( Fransen Van De Putte, DE; Mauser-Bunschoten, EP; Schutgens, RE, 2009) |
| "The diagnosis of acquired hemophilia A (AHA) was made, and treatment with prednisolone (PSL) was started." | ( Abe, T; Azuma, T; Fujiwara, H; Hato, T; Narumi, H; Yakushijin, Y; Yamanouchi, J; Yasukawa, M, 2009) |
| "Three severe haemophilia A patients undergoing ITI regimen who developed CVAD infections resistant to conventional management with antibiotics were treated by ELT according to the institutional technique." | ( Becker, C; Boldt-Macdonald, K; Callaghan, MU; Chitlur, M; Lusher, JM; McLenon, R; Rajpurkar, M, 2009) |
| "Treatment choices for haemophilia patients with inhibitors are suboptimal." | ( Gross, PL; Vaezzadeh, N, 2010) |
| "Anticoagulation therapy and factor VIII deficiency were found to be responsible for the intramural hemorrhage in five patients (83%) and one patient, respectively." | ( Carkman, S; Ergüney, S; Korman, U; Ozben, V; Pekmezci, S; Saribeyoğlu, K; Somuncu, E, 2010) |
| "Diagnosis of acquired hemophilia was made and she was treated with prednisolone and recombinant activated factor VII (rFVIIa)." | ( Miura, I; Nagoshi, H; Nagura, S; Sano, F; Takimoto, M, 2010) |
| "Current treatment of hemophilia A is expensive and involves regular infusions of factor (F)VIII concentrates." | ( Dhadwar, SS; Hortelano, G; Kiernan, J; Wen, J, 2010) |
| "Clinical studies of gene therapy for hemophilia B revealed the limitations of the intramuscular route, compelling an aggressive approach to the study of scale-independent circulatory means of vector delivery." | ( Bridges, CR; Malik, A; Mead, A; Petrov, M; Stedman, HH, 2011) |
| "In most individuals with moderate/mild haemophilia A, FVIII:C levels increase following DDAVP administration to a haemostatic range, thus avoiding the need for FVIII concentrates." | ( Carcao, MD; Feldman, D; Seary, ME, 2012) |
| "HIV+ patients with haemophilia treated with raltegravir for ≥ 6 months were included in this retrospective study." | ( Fusco, F; Gringeri, A; Mago, D; Mangiafico, L; Perja, M; Riva, S, 2012) |
| "In 16 of 18 children with mild hemophilia A, the bleeding symptoms, including the articular or musclar hematoma, were significantly alleviated as a result of DDAVP treatment." | ( Bai, ST; Lu, J; Peng, S; Sheng, GY; Xie, L; Xu, ST, 2011) |
| "The duration of DDAVP therapy for mild hemophilia A is recommended as 3 to 4 days." | ( Bai, ST; Lu, J; Peng, S; Sheng, GY; Xie, L; Xu, ST, 2011) |
| "The management of bleeding in haemophilia patients with inhibitors can be challenging when using monotherapy with either activated prothrombin complex concentrate (APCC) or recombinant activated FVII (rFVIIa) fail." | ( Holme, PA; Holmström, M; Tran, HT, 2012) |
| "Males aged 12-50 years with severe hemophilia A, ≥ 150 days of exposure to FVIII, no FVIII inhibitors, no prophylaxis for > 12 consecutive months in the past 5 years and 6-24 bleeding episodes in the preceding 6 months were randomized 1 : 1 to rFVIII-FS prophylaxis (25 IU kg(-1) , three times weekly) or on-demand treatment." | ( Gercheva, L; Ghinea, M; Goranov, S; Hong, W; Kempton, CL; Lissitchkov, T; Manco-Johnson, MJ; Reding, MT; Rescia, V; Rusen, L; Uscatescu, V, 2013) |
| "Current treatment of hemophilia consists of the administration of recombinant clotting factors, such as factor VIII (FVIII)." | ( Agua-Doce, A; Curotto de Lafaille, MA; Graca, L; Lafaille, JJ; Oliveira, VG, 2013) |
| "Oral treatment is lacking for haemophilia, the rare bleeding disorders, and some severe forms of von Willebrand's disease." | ( Deinum, J; Fex, T; Fjellström, O; Gustafsson, D; Kaspersson, K; McPheat, J; Nielsen, S; Rohman, M; Ulander, J; Wågberg, F, 2013) |
| "FVIII inhibitor development in haemophilia A (HA) patients, especially those with severe manifestations is a serious adverse effect in patients with haemophilia A, and the clinical management of these patients is very difficult as most don't respond to conventional treatment." | ( Ghosh, K; Pinto, P; Shetty, S, 2014) |
| "In low-income countries, haemophilia treatment is not supported by national health services." | ( Dharmarajan, S; Gund, P; Kar, A; Phadnis, S, 2014) |
| "Acquired haemophilia A is a rare life- and limb-threatening bleeding disorder if left untreated." | ( Abeysinghe, H; Copley, HC; Gunawardena, N; Pathirana, UG; Somarathne, MG, 2014) |
| "Patients with severe haemophilia A on prophylaxis (n = 82) had a mean annual rate of treated bleeds of 2." | ( Al Zoebie, A; Andreeva, T; Brunn, M; Gouider, E; Meddeb, B; Mehadzic, S; Nefyodova, L; Rauchensteiner, S; Tueckmantel, C, 2015) |
| "Many paediatric patients with haemophilia who might benefit from radiosynovectomy (RS) for the control of synovitis do not undergo the procedure as there is controversy in the literature regarding the safety of radiation exposure after two cases of acute lymphocytic leukaemia in children with haemophilia treated with (32) P RS were reported." | ( Rodriguez-Merchan, EC; Valentino, LA, 2015) |
| "In people with haemophilia or other congenital bleeding disorders undergoing surgical interventions, haemostatic treatment is needed in order to correct the underlying coagulation abnormalities and minimise the bleeding risk." | ( Coppola, A; Di Minno, MN; Tufano, A; Windyga, J; Yeung, C, 2015) |
| "Treatment of haemophilia A by infusions of the clotting factor VIII (FVIII) results in the development of inhibitors/anti-drug antibodies in up to 25 % of patients." | ( Crauwels, P; Miller, L; Ringler, E; Seitz, R; van Zandbergen, G; Waibler, Z; Weissmüller, S, 2015) |
| "Acquired haemophilia is a rare but life-threatening phenomenon in patients who have undergone surgical treatment." | ( Beishuizen, A; Klaase, JM; Legdeur, MC; Mekenkamp, LJ; Slomp, J; Trof, RJ, 2015) |
| "A diagnosis of acquired hemophilia A was made, and treatment with prednisolone was started, after which APTT improved to 36." | ( Ikebe, T; Itani, K; Miyazaki, Y; Nagamatsu, K; Ogata, M; Ohtsuka, E; Saburi, M; Saburi, Y, 2015) |
| "The immune response of hemophilia A patients to administered FVIII is a major complication that obviates this very therapy." | ( Rossi, RJ; Scott, DW; Wang, H; Yoon, J; Zhang, AH, 2016) |
| "Nine HIV-positive patients with hemophilia were retrospectively studied with a focus on the virological response, changes in the CD4 count, the tendency to bleed, and the response to replacement therapy before and after raltegravir-based antiretroviral therapy (ART)." | ( Gu, S; Lu, H; Sun, H; Wang, J; Xiao, H; Xue, Y, 2016) |
| "Forty-three patients with hemophilia with genotype 1 or 4 HCV were treated with LDV/SOF for 12 weeks." | ( Hanabusa, H; Nagao, A, 2017) |
| "Thus, patients with hemophilia with genotype 1/4 HCV should be treated as early as possible before the onset of cirrhosis." | ( Hanabusa, H; Nagao, A, 2017) |
| "Seven male patients with hemophilia A presenting with progressive swelling of the hand were treated between 2004 and 2013 at a tertiary referral hospital." | ( Abraham, A; Fouzia, NA; Pallapati, SR; Raveendran, S; Srivastava, A; Thomas, BP, 2018) |
| "Improved treatments are needed for hemophilia A and B, bleeding disorders affecting 400 000 people worldwide." | ( Amini, P; Angelillo-Scherrer, A; Bologna, L; Burnier, L; Calzavarini, S; Dewarrat, N; Fernández, JA; Griffin, JH; Ibba-Manneschi, L; Kremer Hovinga, JA; Manetti, M; Matsumura, Y; Melchiorre, D; Prince, R; Quarroz, C; Reina Caro, MD; Rosa, I; Saller, F; Simon, HU; Suardi, S, 2018) |
| "The HCI shows promise for clinical hemophilia studies as a caregiver-based tool for evaluating treatments." | ( Schwartz, CE; Su, J; Zhang, J, 2019) |
| "In patients with non-severe haemophilia A, surgery and bleeding are the main indications for treatment with FVIII concentrate." | ( Beckers, EAM; Cnossen, MH; Coppens, M; Driessens, MHE; Eikenboom, J; Fijnvandraat, K; Kruip, MJHA; Laros-van Gorkom, BAP; Leebeek, FWG; Mathôt, RAA; Mauser-Bunschoten, EP; Meijer, K; Nieuwenhuizen, L; Polinder, S; Schütte, LM; van Hest, RM, 2019) |
| "Forty children diagnosed with hemophilia type A (age, 8-16 years) were randomly allocated to either the treatment group (n = 20) who received a three-phase active therapy with pulsed Nd:YAG laser thrice/week (total energy was 1500 J) plus a physical exercise program for four consecutive weeks, or the placebo group (n = 20) who received placebo laser plus the physical exercise program." | ( Elnaggar, RK, 2020) |
| "A total of 388 HIV-infected non-hemophilia patients who received outpatient treatment at the same institution were included as a control group." | ( Hotta, M; Imai, K; Kikuchi, Y; Kimura, S; Kinai, E; Kiryu, Y; Komatsu, K; Minamimoto, R; Noguchi, T; Ogata, M; Oka, S; Takano, M; Watanabe, A; Yokoyama, K, 2020) |
| "The study was conducted in the Haemophilia Treatment Centre at Aluva, Kerala, India and involved nineteen participants (children, mothers, father and grandmothers) who were selected by theoretical sampling." | ( Biss, T; Hanley, JP; Mathew, S; Narayana Pillai, V; Paul, L; T, R; Thomas, G, 2020) |
| "The development of a safe and effective hemophilia treatment lasted several decades and has been mainly based on clotting factor replacement." | ( Matino, D; Sholzberg, M; Trinchero, A, 2020) |
| "Acquired hemophilia A was treated with prednisolone, cyclophosphamide, and immunoadsorption." | ( Andres, M; Angelillo-Scherrer, A; Dickenmann, M; Jalowiec, KA; Kremer Hovinga, JA; Musa, A; Rovó, A; Taleghani, BM, 2020) |
| "Even though haemophilia has been included under the essential health services and states mandated to continue treatment for these patients despite the global crisis, patients still face challenges in terms of transport and finance." | ( Radhakrishnan, N; Rana, M; Shankar, R; Singh, S, 2021) |
| "However, haemophilia patients in developing countries are still suffering from HA due to insufficient replacement therapy." | ( Meng, Y; Tong, P; Zhang, S; Zhu, H, 2021) |
| "Manual therapy is safe in patients with hemophilia and elbow arthropathy." | ( Cuesta-Barriuso, R; Donoso-Úbeda, E; López-Pina, JA; Meroño-Gallut, J; Pérez-Llanes, R, 2022) |
| "This review provides rationale for haemophilia teams to move beyond traditional outcomes in joint imaging, as well as guidance and evidence on assessment of joint health for potential new treatment modalities, such as gene therapy." | ( la Corte-Rodriguez, H; Martinoli, C; Minno, MNDD; Pasta, G; Samy, I; Stephensen, D; Timmer, MA; Winburn, I, 2023) |
| "The most common complication in hemophilia A (HA) treatment, affecting 25% to 30% of patients with severe HA, is the development of alloimmune inhibitors that foreclose the ability of infused factor VIII (FVIII) to participate in coagulation." | ( Butenas, S; Gunasekera, D; Mann, KG; Olsen, C; Pierce, GF; Pratt, KP; Tan, S; Vir, P, 2023) |
| "The most common complication in hemophilia A (HA) treatment, affecting 25% to 30% of patients with severe HA, is the development of alloimmune inhibitors that foreclose the ability of infused factor VIII (FVIII) to participate in coagulation." | ( Butenas, S; Gunasekera, D; Mann, KG; Olsen, C; Pierce, GF; Pratt, KP; Tan, S; Vir, P, 2023) |
| "People with mild haemophilia (PWMH) experience sporadic bleeds and are less likely to receive an early diagnosis, appropriate treatment and medical care." | ( Cambiaggi, G; Caviglia, H; Daffunchio, C; Galatro, G; Guerrero, V; Landro, ME; Moretti, N; Negrete, G; Neme, D; Primiani, L, 2023) |
| "In Thailand, most hemophiliacs are diagnosed by general practitioners, pediatricians or internists at rural hospitals and are referred to hemophilia specialists at the Hemophilia Treatment Centers (HTCs)." | ( Angchaisuksiri, P; Moonla, C; Natesirinilkul, R; Pongtanakul, B; Sirachainan, N; Sosothikul, D; Suwanawiboon, B; Traivaree, C, 2023) |